Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amid pricing scrutiny, Amgen CEO predicts more value-based contracts
Amid pricing scrutiny, Amgen CEO predicts more value-based contracts
Amid pricing scrutiny, Amgen CEO predicts more value-based contracts
Submitted by
admin
on November 1, 2016 - 9:52am
Source:
BioPharma Dive
News Tags:
Amgen
drug pricing
Pharma CEOs
Robert Bradway
Headline:
Amid pricing scrutiny, Amgen CEO predicts more value-based contracts
Do Not Allow Advertisers to Use My Personal information
